title: [Thromboprophylaxis in patients with coronary aneurysms caused by Kawasaki disease].
abstract: Patients with coronary artery aneurysms caused by Kawasaki disease are at increased risk of coronary thrombosis and ischemia. To prevent coronary thrombosis, long term thromboprophylaxis using anti-platelet drugs, such as aspirin, dipyridamole, ticlopidine, clopidogrel, and abciximab, with or without warfarin is recommended by official guidelines. In fact, aspirin or aspirin with warfarin are the most frequently administered regimen in these patients with coronary aneurysms. However, still there has been paucity of data and no randomized controlled study to determine the efficacy of these drugs. This short article describes the currently accepted practice of thromboprophylaxis in patients with coronary aneurysms caused by Kawasaki disease.
authors.forename: Kenii
authors.initials: K
authors.lastname: Suda
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D003323:Coronary Aneurysm / Q000209:etiology*; D003328:Coronary Thrombosis / Q000517:prevention & control*; D006801:Humans; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D001241:Aspirin